Edinburgh Research Explorer

HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias

Research output: Contribution to journalArticle

  • F J Calero-Nieto
  • A Joshi
  • N Bonadies
  • S Kinston
  • W-I Chan
  • E Gudgin
  • C Pridans
  • J-R Landry
  • J Kikuchi
  • B J Huntly
  • B Gottgens

Related Edinburgh Organisations

Open Access permissions

Open

Documents

  • Download as Adobe PDF

    Rights statement: Available under Open Access

    Final published version, 3.57 MB, PDF document

http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2013175a.html
Original languageEnglish
JournalOncogene
DOIs
Publication statusPublished - 27 May 2013

Abstract

The Lim Domain Only 2 (LMO2) leukaemia oncogene encodes an LIM domain transcriptional cofactor required for early haematopoiesis. During embryogenesis, LMO2 is also expressed in developing tail and limb buds, an expression pattern we now show to be recapitulated in transgenic mice by an enhancer in LMO2 intron 4. Limb bud expression depended on a cluster of HOX binding sites, while posterior tail expression required the HOX sites and two E-boxes. Given the importance of both LMO2 and HOX genes in acute leukaemias, we further demonstrated that the regulatory hierarchy of HOX control of LMO2 is activated in leukaemia mouse models as well as in patient samples. Moreover, Lmo2 knock-down impaired the growth of leukaemic cells, and high LMO2 expression at diagnosis correlated with poor survival in cytogenetically normal AML patients. Taken together, these results establish a regulatory hierarchy of HOX control of LMO2 in normal development, which can be resurrected during leukaemia development. Redeployment of embryonic regulatory hierarchies in an aberrant context is likely to be relevant in human pathologies beyond the specific example of ectopic activation of LMO2.Oncogene advance online publication, 27 May 2013; doi:10.1038/onc.2013.175.

Download statistics

No data available

ID: 8886407